AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial

Core Viewpoint - The pharmaceutical company announced that its ceralasertib combination did not achieve the primary objective in a late-stage clinical trial for advanced lung cancer [1] Group 1 - The clinical trial was focused on advanced lung cancer [1] - The primary goal of the trial was not met, indicating potential challenges in the drug's efficacy [1]